Covaxin safe, well-tolerated in 2-18 years age-group: Bharat Biotech

Bharat Biotech International Limited (BBIL) on Friday announced that its COVID-19 vaccine Covaxin has proven to be safe, well-tolerated and highly immunogenic in paediatric subjects in phase II/III study. A press release from the vaccine maker said the study has been accepted and published in Lancet Infectious diseases, peer reviewed high impact factor journal.

Credits – Source – https://ift.tt/uyj2v8b

The post Covaxin safe, well-tolerated in 2-18 years age-group: Bharat Biotech appeared first on Stay in Gurgaon.

Comments

Popular posts from this blog

Flat sale of flu drugs hints at no unusual rise in infections

Heatwave will be back in Gurugram, temperature may touch 45 degree Celsius

SPAC scrapped, Baring puts CitiusTech on the block for $2.2 bln